Skip to content
Search for:
The Society
Board of Directors
Scientific Advisory Council
Contact
Events Calendar
Mentor Program
Rare Disease Task Force
BOD Trainee Representatives
Awards & Grants
Local Delivery Grants
Lifetime Achievement Award
Young Investigator Award
Dr. Alan M. Gewirtz Memorial Scholarships
Award for Science Outreach or Patient Advocacy
Paper of the Year Awards
Travel Grants
Poster Awards
Science News
Recent Articles
President’s Pick and Perspective
Journal
Archive
Educational Video Library
Support for Ukrainian Scientists
Job Board
Employer Profiles
Employer Registration / Login
Events
Annual Meetings
2024 Annual Meeting
2023 Annual Meeting
Past Annual Meetings
2022 Annual Meeting
2022 Annual Meeting
Agenda
Abstracts & Awards
Exhibitors
Sponsors
Venue & Travel
2021 Annual Meeting
2020 Annual Meeting
Webinars
Events Calendar
Membership
Become A Member or Renew Membership
Featured Members
Search for:
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.
OTS
Immune Stimulation
July 5, 2020
SHARE
Post Views:
422
Buss CG, Bhatia SN.
Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13428-13436.
Pubmed
Previous
Next
Related articles
Hybridization Liquid Chromatography-Tandem Mass Spectrometry: An Alternative Bioanalytical Method for Antisense Oligonucleotide Quantitation in Plasma and Tissue Samples.
Hybridization Liquid Chromatography-Tandem Mass Spectrometry: An Alternative Bioanalytical Method for Antisense Oligonucleotide Quantitation in Plasma and Tissue Samples.
August 5th, 2020
Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
July 5th, 2020
Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
May 15th, 2020
Vaccination against non-mutated neoantigens induced in recurrent and future tumors
Vaccination against non-mutated neoantigens induced in recurrent and future tumors
April 30th, 2020
Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses
Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses
February 29th, 2020
Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization.
Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization.
January 31st, 2020
Page load link
Go to Top